DECA

Denali Capital Acquisition

DECA35

$11.530.00%$11.53

DECA

DECA35

$11.53

0.00%$11.53

Performance History

Key Stats
Open	$11.65
Prev. Close	$0.00
EPS	0.38
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$32.78M

	LOW	HIGH
Day Range	11.53	11.65
52 Week Range	4.05	14.10

Ratios

Revenue	-



EBITDA Margin %	-

EPS	0.38

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Denali Capital Acquisition (DECA)

Denali Capital Acquisition Corp. (DECA) is a publicly traded company on the stock exchange. Its stock price history reflects the performance of the company over time. Investors can use this information to track the fluctuations in DECA's stock price and make informed decisions. The stock price is influenced by various factors such as market conditions, company performance, and investor sentiment.

DECA's stock quote provides the current market price of the stock. Investors can monitor this quote to stay updated on the latest price and make trading decisions accordingly. It is important to note that the stock quote may change throughout the trading day as buying and selling activity occurs.

Sector: Financial Services
Industry: Shell Companies
CEO: Mr. Lei Huang
Headquarters: New York
Employees: 0
Exchange: NASDAQ

add Denali Capital Acquisition to watchlist

Keep an eye on Denali Capital Acquisition

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Denali Capital Acquisition's (DECA) price per share?

The current price per share for Denali Capital Acquisition (DECA) is $11.54. The stock has seen a price change of $11.54 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Denali Capital Acquisition (DECA)?

For Denali Capital Acquisition (DECA), the 52-week high is $14.1, which is 22.24% from the current price. The 52-week low is $4.05, the current price is 184.81% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Denali Capital Acquisition (DECA) a growth stock?

Denali Capital Acquisition (DECA) has shown an average price growth of -6.65% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Denali Capital Acquisition as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Denali Capital Acquisition (DECA) stock price performance year to date (YTD)?

As of the latest data, Denali Capital Acquisition (DECA) has a year-to-date price change of 4.58%. Over the last three months, the change has been 0.48%. Over the past six months, the figure is 59.99%.

help

Is Denali Capital Acquisition (DECA) a profitable company?

Denali Capital Acquisition (DECA) has a net income of $632.54K, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$3.17M. Furthermore, the EBITDA is $0.

help

What is the market capitalization of Denali Capital Acquisition (DECA)?

Denali Capital Acquisition (DECA) has a market capitalization of $32.79M. The average daily trading volume is 11.65, indicating the stock's liquidity and investor engagement.

News

SCILEX HOLDING COMPANY

SEMNUR PHARMACEUTICALS

Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary

SEMNUR PHARMACEUTICALS

SCILEX HOLDING COMPANY

DENALI CAPITAL ACQUISITION CORP.

BUSINESS COMBINATION

REGISTRATION STATEMENT

Oct 16, 2024

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, Provides Timing to File in October 2024 a Registration Statement on Form S-4 with the SEC relating to the Previously Announced Proposed Business Combination Between Semnur and Denali with a Pre-Transaction Equity Value of $2.5 Billion

DENALI CAPITAL ACQUISITION CORP.

SCILEX HOLDING COMPANY

BUSINESS COMBINATION

TRUST ACCOUNT

CONVERTIBLE PROMISSORY NOTE

Oct 11, 2024

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

DENALI CAPITAL ACQUISITION CORP.

SCILEX HOLDING COMPANY

BUSINESS COMBINATION

EXTENSION

Aug 9, 2024